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Abstract:  Glycosphingolipids  are  ubiquitous  molecules  composed  of  a  lipid  and  a 
carbohydrate  moiety.  Their  main  functions  are  as  antigen/toxin  receptors,  in  cell 
adhesion/recognition processes, or initiation/modulation of signal transduction pathways. 
Microbes take advantage of the different carbohydrate structures displayed on a specific 
cell surface for attachment during infection. For some viruses, such as the polyomaviruses, 
binding to gangliosides determines the internalization pathway into cells. For others, the 
interaction  between  microbe  and  carbohydrate  can  be  a  critical  determinant  for  host 
susceptibility. In this review, we summarize the role of glycosphingolipids as receptors for 
members of the non-enveloped calici-, rota-, polyoma- and parvovirus families. 
Keywords:  non-enveloped  virus;  glycosphingolipid;  receptor;  calicivirus;  rotavirus; 
polyomavirus; parvovirus 
 
1. Introduction 
Viruses come in many different flavors and are often broadly classified based on their nucleic acid 
content  (DNA  versus  RNA  virus),  capsid  symmetry  (icosahedral,  helical,  or  complex),  and  the 
presence  or  absence  of  a  lipid  envelope  (enveloped  versus  non-enveloped).  Each  of  these 
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characteristics results in specific replication strategies. However, all viruses are obligate intracellular 
pathogens that rely on the cellular machinery for all stages of the life cycle [1]. Virus infection of cells 
is a multi-step process that generally can be divided into: i) binding to cell surface receptors, ii) fusion 
with  the plasma membrane (some enveloped viruses) or internalization and membrane penetration 
from intracellular compartments (enveloped and non-enveloped viruses), iii) trafficking to the site of 
replication and/or uncoating of the viral genome, iv) replication, iv) production of virion progeny, and 
v) egress. Virus binding to the cell surface is the first step during infection and therefore a determinant 
for tropism. This interaction is also an attractive target for antiviral therapy. Viruses can bind many 
different molecules, including proteins, lipids, and carbohydrates. Some are attachment factors, which 
concentrate virus on the cell surface, while others are receptors or co-receptors that facilitate virus 
entry into cells. Viruses can also use alternate receptors depending on the cell type. Molecules on the 
cell  surface  available  for  virus  binding  are  typically  glycoconjugates  (e.g.,  glycosphingolipids, 
glycoproteins,  and  proteoglycans) [2].  While  the  glycan  portion  usually  extends  furthest  into  the 
extracellular space, virus binding cannot only occur to the membrane distal saccharide but also to the 
membrane proximal protein core. Binding to glycans is in many cases mediated by electrostatic forces 
to negatively charged sialic acid-containing oligosaccharides or portions of glycosaminoglycans. In 
some  cases,  the same oligosaccharide motif can be present on both glycolipids and glycoproteins,  
e.g., histo-blood group antigens (HBGAs). In this review, we will specifically focus on binding of non-
enveloped viruses to glycosphingolipids.  
2. Discussion 
2.1. Structure and function of glycosphingolipids 
Glycosphingolipids  (GSLs)  are  sphingosine-containing  glycolipids [3].  These  amphiphatic 
molecules made up of hydrophobic ceramides (e.g., sphingosine) and hydrophilic carbohydrates are 
integral  parts of most lipid  bilayers together with phospholipids and cholesterol [3]. The chemical 
make-up of these basic building blocks of all living cells contributes to local membrane curvature 
because of the large bulky carbohydrate head group compared to the lipid. The longer the carbohydrate 
chain and the larger the segregation, the more pronounced the membrane curvature [4]. Furthermore, 
the carbohydrates of GSLs are typically aligned perpendicular to the lipids, i.e., lie on the membrane. 
This is contrary to glycoproteins, which extend their carbohydrate chains into the extracellular space. 
Therefore, only the outer surface of the carbohydrate chain is accessible for interactions with ligands, 
e.g., antibodies, lectins, and other GSLs.  
The wide variety of the different GSLs structures is mainly due to differences in number and type of 
the carbohydrate building blocks and/or the length, saturation status, and hydroxylation level of the 
fatty acid chain. GSLs are typically classified based on their charges (neutral, acidic, basic) or core 
structures (lacto-, gala/neolacto-, ganglio-, globo-series) [3,5] (Figure 1). Acidic GSLs contain sialic 
acid or sulfate groups, while basic GSLs are rare. Gangliosides, i.e., GSLs with sialic acid in the 
carbohydrate  chain,  are  found  in  all  series  and  are  made  up  of  ceramide  and  mono-  or 
oligosaccharides [3].  Viruses 2010, 2                                       
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Figure  1.  Schematic  representation  of  discussed  major  core  structures  of  vertebrate 
glycosphingolipids  (GSLs)  (based  on  IUPAC-IUB  Joint  Commission  on  Biochemical 
Nomenclature [6]).  Abbreviations:  Glu:  glucose,  Gal:  galactose,  GluNAc:  N-
acetylglucosamine, GalNAc: N-acetylgalactosamine, Cer: ceramide, R: residue 
 
 
GSLs  are  synthesized  in  the  endoplasmic  reticulum  (ER)  and  Golgi  apparatus  via  sequential 
addition  of carbohydrate units by specific glycosyltransferases and are then transported to the cell 
surface [7]. At the plasma membrane the carbohydrate moiety is exposed to the extracellular space. 
GSLs  are  also  associated  with  intermediate  filaments  within  the  cell  but  this  may  represent  an 
intracellular  transport  intermediate [7].  On  the  cell  surface,  GSLs  are  differentially  expressed  in 
different  cell  types,  tissues,  and  species.  Their  expression  is  normally  tightly  regulated  during 
development and differentiation, but when dysregulation occurs GSLs can also be tumor-associated 
antigens [8].  Accumulation  of  GSLs  can  lead  to  debilitating  diseases  such  as  Tay-Sachs  disease, 
Gaucher’s disease or Krabbe’s disease [3]. Cell surface expression of GSLs can also be modified by 
hydrolysis via membrane-bound sialidases on the cell surface of the same or neighboring cell or by 
shedding  of  GSL-enriched  vesicles.  Collectively  this  leads  to  changes  in  GSL  composition  and 
organization that may have biological consequences with regards to membrane curvature or function 
(e.g., modulating activity of associated proteins or their signaling capabilities).  
GSLs  play  many  important  functional  roles  in  cell  adhesion  and  cell  signaling  based  on  their 
preferential distribution in the outer leaflet of the lipid bilayer on the cell surface [3]. They mediate cell Viruses 2010, 2                                       
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adhesion  by  interaction  with  lectins  (carbohydrate  binding  proteins),  e.g.,  selectins,  siglecs,  or  by 
carbohydrate-carbohydrate  interaction.  Their  role  in  signaling  is  two-fold,  either  as  modulators  of 
signal transduction through association with signal transduction molecules in lipid microdomains (e.g., 
lipid  rafts),  or  the  direct  interaction  (inhibition  or  stimulation)  with  growth  factors  or  integrin 
receptors [3,4,8]. In fact, GSL-enriched microdomains in the plasma membrane are structural units that 
mediate GSL-dependent cell adhesion and signal transduction. GSLs order biological membranes to 
form lipid membrane microdomains. The ceramide portion is particularly important for this clustering 
in microdomains. GSLs can associate with a pre-existing ordered domain or segregate into their own. 
This  results  in  GSL-enriched  microdomains  that  have  different  lipid  compositions  from  other 
membrane regions involved in many cellular events. While part of these microdomains, GSLs can 
influence  the  function  of  membrane-associated  proteins  because  the  sphingolipids  in  these 
microdomains  restrict  fluidity;  thus,  confining  membrane-associated  proteins,  favoring  lateral 
interactions between proteins within a domain, or preventing interactions with proteins in different 
domains. On example of the former is the formation of a complex between the tetraspanin CD9, GM3, 
integrin 3 or 5 that results in reduced cell motility.  Furthermore, proteins in GSL-rich areas tend to 
interacts laterally with confining lipids. For example, the “glycosynapse” is a membrane microdomain 
involved  in  carbohydrate-dependent  adhesion  through  GSL-GSL  interactions  or  GSL-dependent 
modulation of adhesion receptors like integrins.  
GSLs  also  directly  function  as  receptors  for  cellular  molecules  (hormones,  interferons  and 
lymphokines)  or  microbes  (bacteria,  viruses)  and  microbial  products  (bacterial  toxins)  via  their 
carbohydrate structure [8,9]. While many different microbes bind to GSLs, a few common features of 
these interactions are seen repeatedly [9]. Terminal or internal (non-terminal) portions of the GSL can 
function as the minimal binding site. Shorter GSLs with binding epitopes in close proximity to the lipid 
bilayer are utilized more frequently as receptors, often facilitating internalization. A few changes in the 
amino acid sequence of closely related strains/variants in or around the receptor binding site can lead to 
differences in binding specificities. Carbohydrate-microbe interactions are typically of low affinity and 
are strengthened by multivalency of repeating units  (e.g.,  icosahedral  virions,  repeating saccharide 
units).  One  or  more  of  these  features  are  found  in  all  microbe-GSL  interactions,  including  the 
interaction of non-enveloped viruses with GSLs, which is the topic of this review.  
2.2. Caliciviridae 
Caliciviruses are small non-enveloped icosahedral viruses with a single-stranded, plus-sense RNA 
genome  of  7.4-8.3  kb [10].  They  are  divided  into  the  genera  Norovirus  (NoV),  Sapovirus  (SaV), 
Vesivirus (VeV), Lagovirus (LaV), and Nebovirus (NeV), as well as the recently proposed “Recovirus” 
(ReV) [10-12]. Caliciviruses in general exhibit a wide range of host and tissue tropisms, causing a 
variety  of  diseases [10].  Only  members  of  the  NoV  and  SaV  genera  infect  humans  causing 
gastroenteritis. VeV includes the feline calicivirus (FCV), which causes respiratory disease in cats. 
LaV  includes  rabbit  hemorrhagic  disease  virus  (RHDV)  that  causes  a  necrotizing  hepatitis  with 
associated hemorrhaging and high mortality rates in rabbits. NeV and “Recovirus” have only recently 
been  described  and  include  bovine  enteric  virus  Newbury  agent-1  (Newbury1)  and  the  rhesus 
macaques Tulane virus (TV), respectively. Viruses 2010, 2                                       
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The genomes are typically organized into either two (LaV, SaV, NeV) or three (NoV, VeV, ReV) 
major open reading frames (ORF) [10-12]. ORF-1 encodes a non-structural polyprotein processed by 
the virally encoded 3C-like cysteine protease. ORF-2 encodes the major capsid protein VP1 that forms 
the  viral  capsid [10].  ORF-3  encodes  the  minor  capsid  protein  VP2,  of  which  1-2  copies  are 
incorporated into the capsid [13]. A fourth ORF was recently identified by bioinformatics for murine 
norovirus (MNV) [14]. In the case of SaV, LaV, and NeV, VP1 is part of the ORF-1 polyprotein [10].  
The viral capsid is composed of 180 monomers of the major capsid protein VP1, which is organized 
into 90 dimers and exhibits a T=3 icosahedral symmetry [15-19]. The capsid contains two domains, the 
shell (S) and the protruding (P) domains, which are separated by a flexible hinge [15-17,20]. The S 
domain forms a smooth shell around the viral genome, but is unable to bind to receptors [21,22]. The P 
domain contains receptor-binding regions and dimerizes forming arch-like structures on the capsid 
surface [23-27]. It is further subdivided into P1 (stem of arch) and P2 (top of arch) subdomains. P2 is 
the most variable region and contains the carbohydrate-binding motif [25-27]. Expression of VP1 in 
various insect, animal, or plant expression systems results in formation of virus-like particles (VLPs) 
that antigenically and morphologically resemble infectious virus [28-33].  
The study of calicivirus biology is hampered by the lack of efficient cell culture systems and only 
MNV [34], the SaV porcine enteric calicivirus (PEC) [35], and FCV [36] are efficiently cultured in 
continuous cell lines. Based on studies in culture as well as using VLPs, it appears that a common 
feature of caliciviruses is their ability to attach to polymorphic glycoconjugates (GSL, glycoproteins or 
glycosaminoglycans). Many human noroviruses (HuNoV) and RHDV bind to HBGAs, while MNV-1 
attaches to sialic acid on gangliosides (see below). Furthermore, the F9 strain of FCV attaches to 2,6-
linked  sialic  acid  on  N-linked  glycoproteins [37]  while  some  other  FCV  isolates  can  infect  cells 
independently of 2,6-linked sialic acid [38]. Entry of FCV is then mediated by the feline junctional 
adhesion molecule A (fJAM-A), a transmembrane Ig-like protein [39]. Thus far fJAM-A constitutes 
the only known functional receptor in the calicivirus family. Virus entry into permissive cells then 
occurs  either  by  pH-dependent,  clathrin-mediated  endocytosis  for  FCV [40]  or  a  pH-independent, 
cholesterol- and dynamin-dependent endocytosis in the case of MNV [41-43].  
2.2.1. Noroviruses (NoV) 
NoV are emerging pathogens [44-47] that have been isolated from an increasing number of animal 
species,  including  mice,  cows,  pigs,  and  sheep [48-52].  NoV  are  classified  into  five  different 
genogroups (GI-GV) and at least 40 different genotypes [53,54]. Members of GI, GII and GIV infect 
humans, whereas GIII infects  only bovine species [53] and GV only mice [48]. Currently, HuNoV 
strains belonging to genogroup II genotype 4 (GII.4) are the predominant outbreak strains worldwide 
(e.g.,  [55-57]).  Early  steps  in  the  norovirus  life  cycle  (e.g.,  receptor  binding)  are  determinants  of 
norovirus tropism [58] and thereby determine the outcome of a viral infection.  
2.2.1.1. Human noroviruses (HuNoV) 
HuNoV are responsible for the majority of acute viral gastroenteritis worldwide with an estimated 
23  million  infections  in  the  US  per  year  [10,59].  HuNoV  infections  affect  all  age  groups  and 
transmission occurs through contaminated food or water and person-to-person contact via the fecal-oral Viruses 2010, 2                                       
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route  or  virus-containing  aerosols  [10].  Outbreaks  frequently  occur  in  enclosed  facilities,  such  as 
hospitals,  nursing  homes,  and  cruise  ships.  Although  infections  are  usually  mild  and  non  
life-threatening in healthy adults, they pose a serious threat to the immunocompromised and elderly. 
An  important  complication  of  norovirus  containment  is  the  spread  of  virus  by  asymptomatically 
infected people as well as patients, who have recovered from disease symptoms, but are still shedding 
virus. However, despite their impact on public health, no drugs or vaccines are available for treatment 
or prevention [10]. 
Despite the inability of HuNoV to grow reproducibly in cultured cells [60], the availability of VLPs 
has enabled binding studies and the identification of attachment receptors. These VLPs are generated 
by  spontaneous  self-assembly of  the capsid  protein VP1,  which  morphologically and antigenically 
resemble native virions [29]. Most HuNoV bind to HBGAs (reviewed in: [44,61,62]), while some can 
also bind to heparan sulfate [63] or sialic acid [64] (Table 1). 
Table 1. Summary of viruses and their glycosphingolipid receptors discussed in the text 
and respective references. 
VIRUS  GLYCOSPHINGOLIPID 
RECEPTORS 
OTHER 
RECEPTORS 
REFERENCE 
Caliciviridae       
Norovirus       
Human Norovirus 
(HuNoV) 
Histo-blood group antigens (HBGA) 
on type 1, 2, and 3 GSLs 
Heparan sulfate, 
sialic acid on SLe
x 
 [44,61-64] 
 Murine Norovirus 
(MNV) 
Terminal  α2,3-linked  sialic  acid  on 
GD1a and GT1b 
   [70]  and  this 
article 
Bovine Norovirus 
(BoNoV) 
αGal of HBGA     [71] 
Lagovirus       
Rabbit Hemorrhagic 
Disease Virus (RHDV) 
A and H type 2 HBGA     [72] 
       
Reoviridae       
Rotavirus    Integrins α2β1, α4β1, αvβ3, 
αxβ2, hsc70 
 [73] 
Neuraminidase-sensitive       
Porcine Rotavirus:  
OSU strain 
Sialic acid on GM3     [74,75] 
Porcine Rotavirus: CRW-8 
strain 
Terminal and internal α2,3-linked 
sialic acid on GD1a 
   [76] 
Simian Rotavirus:  
SA11 strain 
Sialyl-galactose  on  NeuGcGM3, 
sialylneolactotetraosylceramide, 
GM2, and GD1a 
   [77] Viruses 2010, 2                                       
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Table 1. Cont. 
VIRUS  GLYCOSPHINGOLIPID 
RECEPTORS 
OTHER 
RECEPTORS 
REFERENCE 
Bovine Rotavirus: 
NCVD strain 
Sialyl-galactose (NeuGc/NeuAcα3-
Galβ) on NeuGcGM3, 
sialylneolactotetraosylceramide, 
GM2, and GD1a 
   [77] 
Rhesus Rotavirus: RRV 
strain 
N-acetyl neuraminic acid     [78] 
Neuraminidase-insensitive       
Bovine Rotavirus: 
UK strain 
Sialyl-galactose (NeuAc) on 
NeuGcGM3, GM1, GD1a, GM2, 
sialylneolactotetraosylceramide 
   [77] 
Human Rotavirus: 
KU, MO, DS-1, Wa strains 
GM1     [76,79] 
Polyomaviridae       
Murine Polyomavirus 
(MPyV) 
Terminal α2,3-linked sialic acid on 
GD1a and GT1b 
Integrin α4β1   [80-83] 
Simian Virus 40 (SV40)  GM1  Class I MHC   [80,84,85] 
BK Virus (BKV)  α2,8-linked disialic acid on GD1b 
and GT1b 
Unknown glycoprotein   [86,87] 
JC Virus (JCV)  Terminal α2,3-linked sialic acid on 
GT1b 
Serotonin receptor 
5HT2aR; Terminal α2,6-
linked sialic acid on an 
unknown glycoprotein 
 [88-91] 
Merkel Cell Polyomavirus 
(MCPyV) 
Terminal α2,3-linked sialic acid and 
α2,8-linked disialic acid on GT1b 
   [92] 
       
Parvoviridae       
Erythrovirus       
Human Parvovirus B19  HexNAcβ1,3Gal on globoside Gb4 
(P antigen), SSEA-3, SSEA-4, and 
nLc4 
Integrin  α5β1,  autoantigen 
Ku80 
 [93-96] 
Simian Parvovirus  Globoside and Forssmann antigen     [97] 
Dependovirus       
Bovine Adeno-associated 
Virus (BAAV) 
Unknown ganglioside     [98] 
 
HBGAs consist of complex glycans and are found in a variety of cell types, including red blood 
cells [65] and intestinal epithelial cells [66]. They can also be secreted into body fluids, such as breast Viruses 2010, 2                                       
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milk and saliva [67,68]. HBGAs are generated by an ordered addition of monosaccharides by glycan 
modifying enzymes. The antigens producing polymorphic ABH, Lewis, and secretor phenotypes can be 
found on a variety of N- and O-linked glycoproteins, as well as GSLs of the lacto-, neolacto-, ganglio-, 
and globoseries [6,67,69] (see Table 2 and Figure 1).  
Table 2. Disaccharide precursors of glycoconjugates [6,67]. 
Name  Structure  Residue (R) 
Type 1  Galβ1-3, GlcNAcβ1-R  N-,O-glycoproteins, GSLs of the lactoseries (Lc) 
Type 2  Galβ1-4, GlcNAcβ1-R  N-,O-glycoproteins, GSLs of the neolactoseries (nLc) 
Type 3  Galβ1-3, GalNAcα1-R  O-glycoproteins (core 1), GSLs of the ganglioseries (Gg) 
Type 4  Galβ1-3, GalNAcβ1-R  GSLs of the globoseries (Gb) 
 
The biosynthetic pathway of HBGAs involves the linkage of glycans and oligosaccharide chains to a 
disaccharide  precursor  [5,8,99]  (Figure  2).  Addition  of  fucose  by  an  alpha-1,2-fucosyltransferase 
generates the H antigens, which can be followed by the biosynthesis of the A or B antigens through the 
activities  of  the  blood  group  A  or  B  transferases,  respectively.  There  are  two  functional  
alpha-1,2-fucosyltransferases known in humans, encoded by two genes, FUT1 and FUT2. FUT1 is 
preferentially expressed in ecto- and mesodermally derived tissue (e.g., red blood cells), producing 
mostly type 2 antigens, whereas FUT2 based type 1 antigens are found in endodermally derived tissue 
(e.g., epithelial cells in the intestinal tract) [100]. Individuals that lack FUT1 produce the rare Bombay 
phenotype, characterized by the lack of ABH antigens on red blood cells [101]. Individuals that lack 
FUT2 produce the non-secretor phenotype (about 20% of Caucasians) and are characterized by the 
absence  of  ABH  antigens  in  body  fluids  and  various  epithelial  cells [68].  FUT3  is  an  
alpha-1,4-fucosyltransferase and produces the Lewis antigens Le
A (type 1) and Le
X (type2) in non-
secretors and Le
B (type 1) and Le
Y (type 2) in secretors. A-type epitopes are also found on type 3 
(ganglio) and type 4 (globo) oligosaccharide chains [65]. 
Noroviruses  recognize  polymorphic  HBGAs  on  type  1,  2  and  3  GSL  as  attachment  receptors 
[102.106] via the P2 subdomain of VP1 [21, 25-27]. HBGA-binding is diverse and strain-specific, as 
some strains bind exclusively to either ABH or Lewis, both, or neither (e.g., [102,105,107,108]). This 
was  demonstrated in  multiple studies  using VLPs from a variety of NoV strains and testing VLP 
binding to saliva from secretors or non-secretors or individuals with different ABH and Lewis profiles 
as  well  as  synthetic  oligosaccharide  chains  containing  human  HBGA  epitopes.  However,  these 
structures can be present on either lipids or proteins (see Table 1) and only a few recent studies have 
investigated NoV binding to carbohydrates in complex with its core. Binding of Norwalk virus (NV) to 
GSLs  was  first  demonstrated  using  radioactively-labeled  VLPs  in  thin-layer  chromatogram  (TLC) 
binding assays [109]. NV VLPs bind to all type 1 and 2 secretor epitopes but not B-types, as well as 
complex GSLs on blood group O and A but not B erythrocytes. Furthermore, studies using quartz 
crystal microbalance with dissipation (QCM-D) monitoring and TLC show that NV and Dijon (GII.4) 
attach to the H type 1 antigen on GSL but not Le
A [110]. Interestingly, a threshold concentration of H 
type 1 GSL was required for binding of both strains. However, the threshold of Dijon binding was one 
order of magnitude higher than that of the NV strain, indicating a lower affinity of Dijon to H type 1 Viruses 2010, 2                                       
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GSLs. The authors propose that binding of virus to a few GSL molecules recruits further molecules 
into the binding area to increase affinity of the interaction [110]. Furthermore, one study compared a 
large panel of VLPs from five GI genotypes and eight GII genotypes for binding to ABH and Lewis 
HBGAs attached to type1 or type 2 core structures by ELISA and Biacore analysis [111]. Several VLPs 
were identified that showed slower dissociation rates in the Biacore experiments and stronger binding 
of VLPs in ELISA to type 1 carbohydrates compared to type 2 carbohydrates; thus demonstrating that 
core structures are also important for VLP recognition. This is partially consistent with the previous 
observation that NV binds type-1 and -3 HBGA (but not type 2) on gastroduodenal epithelial cells of 
secretor individuals [106]. However, the relevance of this  differential  recognition during norovirus 
pathogenesis remains unknown. In addition, a recent study also identified binding of HuNoV VLPs to 
negatively  charged  sialylated  neoglycoproteins [64]  instead  of  neutral  HBGAs.  Since  the  same 
sialylated structures are also present on GSL, this raises the possibility that HuNoV can also bind to 
acidic GSL. VLPs from the Chron1 (GII.3) and the Dijon strains recognize sialyl Lewis x (SLe
X) and 
the structural analogues sialyl-diLewis x (2SLe
X) and sialylated type 2 antigen in addition to secretor 
gene-dependent glycans (Figure 3) [64]. Binding to SLe
X is strictly sialic acid-dependent, since a non-
sialylated control glycan (Lex-
HSA) does not bind to these VLPs. Also, both VLPs do not bind to SLe
A 
indicating that the fucosyl residue of SLe
X is not absolutely required and that a terminal sialic acid is 
not sufficient for binding. In contrast, NV VLPs do not recognize any of the sialylated conjugates and 
only  recognized  secretor  gene-dependent  glycans  on  GSL  [64].  So  far  no  GI  strains  have  been 
described to bind sialylated antigens [54]. 
Furthermore,  epidemiological  and  challenge  studies  also  reveal  a  connection  between  HBGA 
expression, secretor status and susceptibility to HuNoV strains [61,105,108,112,113]. For example, a 
challenge study with NV showed that non-secretor individuals are resistant to infection [105], and NV 
VLPs bind to gastroduodenal cells from secretors but not non-secretors [106]. In addition, NV VLPs 
hemagglutinate erythrocytes and bind to saliva from blood group A, AB, and O individuals, but less 
from blood group B [102,104,114]. Non-secretors are typically less likely to be infected [115,116]. 
However, this is not universal as VLPs from an epidemic GII.4 strain from 2002 (Farmington Hills) 
bind  to  saliva  from  both  secretors  and  non-secretors [117].  Studies  using  a  GII.2  strain  (Snow 
Mountain) showed that blood type and secretor status did not correlate with infection [116] and a group 
of genetically susceptible individuals never got infected [105], suggesting that additional factors may 
exist that determine HuNoV susceptibility.  
Analysis of crystal structures of the P domains from strains in two genogroups NV (GI.1) or VA387 
(GII.4) in  complex with  oligosaccharides  from  HBGA reveals  two distinct and spatially separated 
carbohydrate  binding  sites  in  the  P2  subdomain [25-27].  NV  and  VA387  bind  the  same  ligand  
(A trisaccharide) using two independent sites and binding modes [25-27]. NV binds to synthetic H type 
and A type carbohydrates via hydrogen bonds from a binding pocket at the interface of the P-dimer 
[25,26], while VA387 binds to the A and B antigen via hydrogen bonds to specific amino acids in the 
E’F’-loop in each P domain monomer [27]. NV VLP binding to the H type pentasaccharide is mediated 
primarily via the -fucose and -galactose groups [26] while -fucose is less important in case of A 
type trisaccharide binding and most hydrogen bonds are with the GalNAc group [25,26]. Binding of 
the A type trisaccharide is mediated primarily through hydrogen bonding to the -fucose group with Viruses 2010, 2                                       
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weaker, long-distance interactions to the -galactose ring. Some amino acids in the E’F’-loop in the 
VA387 structure could only be resolved in the complexed structure, indicating a degree of flexibility in 
the binding pocket that becomes stabilized upon receptor binding [27]. Additionally, the same amino 
acids in the NV binding pocket can interact with different molecules in the oligosaccharide chain. 
Alpha-1,2-fucose is preferentially bound in the H type, while the same amino acids interact with the 
terminal  GalNAc  in  the  A  type  structure.  A  superimposition  of the  GII.4  structure  (VA387)  with 
modeled  structures  of  other  GII  P  domains  showed  that  the  binding  site  differs  not  just  between 
genogroups, but also between different genotypes within one genogroup [118].  
Figure 2. The biosynthetic pathway of type 1 (Lc) and type 2 (nLc) HBGAs. The pathway 
starts  with  a  disaccharide  precursor  of  type1  or  type  2  carbohydrate  chains.  Type  1 
disaccharide precursors are 1-3, and type 2 are 1-4 linked. FUT1 specifically generates 
type 2 H antigens, while FUT2 preferentially produces the type 1 H antigens, although it 
also has activity on the type 2 chain [109]. Further modification of the H type1/2 by A or B 
enzymes synthesizes the respective tetrasaccharides, adding the A and B antigens. FUT3 
generates the trisaccharides Lewis A (Le
A) or Lewis X (Le
X) in non-secretors, as well as 
Le
B and Le
Y in secretors, by attaching 1-4 fucose on type 1 chains or 1-3 fucose on type 
2  chains.  Abbreviations:  Glu:  glucose,  Gal:  galactose,  GluNAc:  N-acetylglucosamine, 
GalNAc: N-acetylgalactosamine, Cer: ceramide, R: residue 
 
 
Variations  in  and  around  the  HBGA  binding  domain  result  in  altered  HBGA  binding  and 
antigenicity  and  may  be  a  mechanism  by  which  noroviruses  escape  immune  response  and  herd 
immunity while retaining receptor binding activity [118]. For instance, a single amino acid exchange at 
position 395 in the P2 domain of the Grimsby strain (secretor-dependent) allows the virus to infect Viruses 2010, 2                                       
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non-secretors  and  thereby  expand  into  a  naïve  population [118].  Additional  changes  that  alter 
antigenicity then allow the virus to escape herd immunity [54,117,118]. Thus, new progeny variants are 
capable  of  infecting  the  same  individuals  that  were  previously  infected  or  previously  resistant 
individuals. 
Figure 3. Comparison of some discussed carbohydrate structures used during attachment 
of human and mouse NoV. Schematic representation of the HuNoV attachment receptors 
(H type 1, H type 3 A, Sialyl  Lewis  X)  and  MNV-1  ganglioside attachment receptors 
(GD1a  and  GT1b).  Abbreviations:  Glu:  glucose,  Gal:  galactose,  GluNAc:  N-
acetylglucosamine, GalNAc: N-acetylgalactosamine, Cer: ceramide, R: residue 
 
 
2.2.1.2. Murine Norovirus 
The first murine norovirus (MNV) strain, MNV-1, was discovered in 2003 and was the first member 
of GV [48]. Serologic analysis of mice from research colonies in North America, Europe and Asia 
demonstrated  that  22-64%  of  all  mice  had  antibodies  against  MNV-1  or  were  positive  for  MNV 
genome,  which  makes  MNV  the  most  prevalent  virus  in  research  mice   [119-124].  MNV  shares 
pathogenic properties with HuNoV as it is an enteric virus that replicates in the intestine and is shed in 
feces, resulting in fecal-oral spread [125]. While the tropism for HuNoV remains unknown, MNV 
efficiently replicates in murine macrophages and DCs, but not in human macrophages and DCs or 
other cell types regardless of their origin [34,125]. MNV-1 enters permissive murine macrophages and 
DCs in a pH-independent manner [42]. MNV-1 does not bind to commercially available synthetic 
HBGAs [54]. Instead, binding of MNV-1 to the macrophage cell surface is partially neuraminidase-
sensitive and ganglioside-dependent  [70]. TLC demonstrated that murine macrophages express the 
gangliosides GD1a, GM1, GA1 (Figure 4) and MNV-1 binds to GD1a, but not GM1 and GA1 by Viruses 2010, 2                                       
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ELISA [70]. This suggests that the minimal binding epitope is the terminal sialic acid found in GD1a. 
The same terminal sialic acid is also found in GT1b and MNV-1 binds to GT1b by ELISA verifying 
this  observation  (Taube,  S.  and  Wobus,  C.  E.  unpublished  observation)  (Figure  3,  Table  1). 
Ganglioside depletion and reconstitution studies with GD1a and GA1 demonstrate that MNV-1 and 
two other MNV strains (WU11 and S99) bind specifically to GD1a on murine macrophages [70].  
In summary, data from both HuNoV and MNV highlight the use of carbohydrates during binding using 
at times the same side group, i.e., usage of sialic acids (MNV-1, HuNoV strains Chron1 and Dijon),  
or  similar  carbohydrate  backbones,  i.e.,  Gal-GalNAc-Gal  sequence  in  GD1a/GT1b  and  H  type  3 
(Figure 3).  
Figure  4.  Comparison  of  discussed  carbohydrate  structures  used  during  attachment  of 
bovine  NoV.  Schematic  representation  of  the  BoNoV  attachment  receptor  (Gal  and  
Gal-Le
X) in comparison to the human HBGA receptor H type 2 B-antigen. Abbreviations: 
Glu:  glucose,  Gal:  galactose,  GluNAc:  N-acetylglucosamine,  GalNAc: 
N-acetylgalactosamine, Cer: ceramide, R: residue 
 
2.2.1.3. Bovine Norovirus (BoNoV)  
The bovine norovirus Newbury2 (NB2) (Bo/Newbury2/1976/UK) was first isolated in the UK in 
1976 from calves with diarrhea and is the type strain of GIII [71,126]. Labeling of bovine gut sections 
with VLPs from NB2 matched the staining pattern of the Gal epitope detected by either a mAb or the 
GS1-B4 lectin, but not that of ABH or Lewis antigens and was sensitive to -galactosidase treatment Viruses 2010, 2                                       
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[71]. Using a wide range of synthetic oligosaccharides, the αGal epitope reacted strongest with NB2 
VLPs, with αGal-Le
X being the only other oligosaccharide detectable by ELISA. Saturation transfer 
difference (STD) nuclear magnetic resonance (NMR), which allows identification and characterization 
of ligand binding to  large receptor proteins  at  an atomic resolution, identified the 1,3-glycosidic 
linkage of αGal as the central recognition element of Galα3GalβOMe in binding to NB2 VLPs [71] 
(Figure 4). Even though the αGal epitope is structurally related to the H type 2 B-antigen, NB2 is not 
likely to infect humans, because the αGal epitope is absent from human duodenal cells, and NB2 does 
not hemagglutinate human B blood group erythrocytes [71]. 
2.2.2. Lagovirus 
Rabbit  Hemorrhagic  Disease  Virus  (RHDV),  the  type  species  in  the  genus  LaV,  was  the  first 
calicivirus shown to bind HBGA [72]. It causes systemic infection in rabbits with epidemics of acute 
fatal hepatitis, but the mechanism by which RHDV infects rabbits is still unclear [72,127]. RHDV 
replicates in hepatocytes and large numbers of virus are found in liver tissue from infected animals 
[128,129]. However, recombinant VLPs or virions fail to bind to liver sections but instead bind to 
HBGA on rabbit epithelial cells of the upper respiratory and digestive tracts [72,130].  
RHDV  hemagglutinates  human  and  rabbit  red  blood  cells  [72,128,129].  Hemagglutination  is 
dependent on the presence of ABH blood group antigens, because the rare Bombay phenotype, which 
completely lack ABH antigens, is not agglutinated [72]. Furthermore, agglutination was inhibited by 
saliva from secretor individuals, but not from non-secretors [72]. RHDV VLPs and virions from liver 
extracts specifically bind synthetic A and H type 2 blood group oligosaccharides, but not Le
B or Le
Y 
antigens [72]. The L-fucose is the minimal structural epitope required for RHDV VLP binding because 
VLPs very selectively recognized -L-Fuc-OMe but not -D-Gal-OMe by STD-NMR [131]. 
Similarly to human secretor status, nonfunctional alleles of FUT genes confer an important genetic 
resistance  marker  to  RHDV  infection.  Generation  of  the  H  type  2  HBGA  requires  an  
alpha-1,2 fucosyltransferase [72]. In rabbits three alpha-1,2 fucosyltransferase genes are known, Fut1, 
Fut2, and Sec1. Nonfunctional alleles in any of these loci are known to occur [127]. Mutations leading 
to  the  H  type  2-negative  phenotype  are  predominant  in  areas  with  a  high  impact  of  RHDV  as 
demonstrated by genotyping buccal epithelial cells from wild rabbits [127]. In addition, age-dependent 
expression  of  H  type  2  correlates  with  an  increase  in  susceptibility  RHDV  infection [72].  Young 
rabbits are protected from infection, and their tracheal tissues were almost devoid of A and H type 2 
antigens with only very weak binding of VLPs [132,133]. Since HBGA are undetectable on rabbit 
hepatocytes, it is unlikely that RHDV uses HBGAs as receptors on hepatocytes. Instead HBGAs likely 
mediate infection of upper respiratory and/or digestive tract epithelial cells. However, whether HBGAs 
constitute a functional receptor or attachment factor remains to be investigated. 
2.3. Rotaviruses 
Rotaviruses  are  members  of  the  Reoviridae  family  [134].  They  are  the  leading  cause  of 
gastroenteritis in children worldwide and are important veterinary pathogens (e.g., cattle, sheep, swine, 
and poultry). Rotavirus infections in nature occur mostly in a species-specific manner. The virus targets 
the mature enterocytes at the tip of the intestinal villi in the small intestine of all ages but disease is Viruses 2010, 2                                       
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primarily  observed  in  the  young.  The  watery  diarrhea  is  caused  by  multiple  factors  that  include 
malabsorption and a secretory component [135].  
The rotavirus genome is composed of 11 segments of double-stranded RNA, which are enclosed in 
triple-layered particles of approximately 100 nm in diameter [73]. The inner capsid layer is formed by 
VP2  and  encloses  a  less  well-defined  subcore  that  also  contains  the  VP1  (RNA-dependent  RNA 
polymerase)  and  VP3  (guanylyltransferase  and  methylase),  both  of  which  form  a  complex  at  the 
icosahedral five-fold vertices. The intermediate layer is made up of VP6, and the outer layer consists of 
780 molecules of the glycoprotein VP7 and 60 dimers of spikes of VP4 [73,134]. Both VP7 and VP4 
interact with cellular receptors and facilitate virus entry into cells. Virus entry is a multi-step process 
that depends on multiple cellular molecules: N-acetylneuraminic (sialic) acid residues, integrins 21, 
41, v3, x2, heat shock cognate protein (hsc) 70, and certain gangliosides [73,136] (Table 1). 
Trypsin cleavage of VP4 leads to conformational changes in the capsid and is required for virus entry 
(but not binding). The cleavage yields the C-terminal VP5* domain of VP4 and a N-terminal VP8* 
domain of VP4, both of which remain associated with the particle. A sequential model was proposed 
for the early steps of rotavirus entry into cells [134]. First, the VP8* domain of VP4 interacts with 
sialic  acid  residues  (either  on  glycosphingolipids  or  glycoproteins)  that  induces  a  conformational 
change in VP4, exposing VP5*. Second, the VP5* domain interacts with 21 integrin. Third, the 
following interactions occur in a yet to be determined sequence of events sequentially or alternatively: 
VP5* with hsc70, VP5* with 21, VP5* with 41, VP7 with v3 integrin, and (depending on the 
strain) VP7 with x2 or 41 integrins. However, 21 integrin is not necessary for attachment to 
cells  [137].  Interaction  with  these  multiple  receptors  occurs  at  least  in  part  in  lipid  raft 
microdomains [134].  VP8*  causes  an  opening  of  the  tight  junctions,  which  may  be  required  in 
polarized epithelial cells, which express integrins primarily on the basolateral surface. Based mostly on 
studies  in  non-polarized  epithelial  African  green  monkey  kidney  cells  (MA104)  with  the  rhesus 
rotavirus (RRV) strain, virus entry then occurs in a caveolin-, clathrin-independent but dynamin- and 
cholesterol-dependent manner. Plasma membrane penetration is then mediated by VP5*, which binds 
lipids and permeabilizes membranes [138,139]. Once the virions reach the cytoplasm, the triple-layer 
particle  sheds  its  outer  layer  to  yield  the  transcriptionally  active  double-layer  particle  and  viral 
replication proceeds in the cytoplasm.  
For the purpose of this review, we will focus only on the interaction of rotavirus (via VP8*) with its 
glycosphingolipid attachment receptor. The recognition that sialic acids play an important role during 
rotavirus entry comes from early studies in which some strains had hemagglutination activity of red 
blood cells and neuraminidase treatment of cells reduced virus binding and infection of some strains 
(e.g.,  [140-144]).  In  general,  the  easily  culturable  animal  rotaviruses  bound  to  host  cells  in  a 
neuraminidase-sensitive manner while human rotaviruses did not [145]. This led to the classification as 
“neuraminidase-insensitive  =  sialic  acid-independent”  versus  neuraminidase-sensitive  = sialic acid-
dependent”  rotaviruses.  This  controversial  classification of sialic acid-dependent  and  –independent 
rotaviruses strains has now been laid to rest as recent structural data [76] provides conclusive evidence 
that  neuraminidase-insensitive  viruses  bind  to  internal  sialic  acids  resistant  to  the  action  of 
neuraminidases. Therefore, all rotaviruses are thought to bind to sialic acids but the relative position 
and/or linkage of the sialic acid residue may differ [146]. Strains that dependent on terminal sialic acid Viruses 2010, 2                                       
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as binding partners also typically hemagglutinate erythrocytes. However, viruses from either group 
infect polarized cells through either the apical or basolateral membrane with a slight preference for the 
latter  [147].  This  likely contributes  to  the observed extraintestinal spread of  rotaviruses [148,149]. 
Furthermore,  important  for  rotavirus  pathogenesis  is  the  finding  that  rotavirus-binding  competent 
gangliosides are expressed in tissues in an age-dependent manner, which is one likely reason for the 
observed age-dependent disease manifestation. 
2.3.1. Neuraminidase-sensitive strains 
2.3.1.1. Porcine rotaviruses (OSU, CRW strains) 
Porcine rotaviruses are important agricultural agents that bind to cells in a neuraminidase-dependent 
manner [74,75,150-152]. Purified GM2 and GM3 have the greatest inhibitory effect in preventing 
binding of iodinated triple-layered OSU particles to porcine enterocytes and MA104 cells (embryonic 
rhesus monkey kidney cells) [74,153]. Some inhibition was seen with GM1 and GD1a, even less with 
GD1b  and  GT1b  and  no  inhibition  with  GA1  and  GA2  [74,153].  To  correlate  these  findings  to 
pathogenesis, GSLs were isolated from pooled intestines of newborn to four week-old piglets and 
porcine GM3 (either N-glycolylneuraminic acid [NeuGc] or N-acetylneuraminic acid [NeuAc]) was 
identified as the attachment receptor of OSU [74,75]. In vitro, iodinated triple-layered but not double-
layered particles bind to intestinal NeuAcGM3, NeuGcGM3, and bovine GM3 immobilized on TLC 
plates. In culture, intestinal GM3 blocks binding and infection of MA104 cells with NeuGcGM3 being 
two- to three-fold more effective than NeuAcGM3 [75]. Furthermore, binding of triple-layered OSU to 
Lec-2 cells, which have 90% reduced sialylation of glycolipids and –proteins, is reconstituted to levels 
greater than that of control cells by addition of exogenous NeuGcGM3 [75]. In piglets, NeuGcGM3 
rapidly declines in the first four weeks of life in the intestine while NeuAcGM3 is found in lower 
amounts  and only gradually decreases  over the first 16 weeks, suggesting NeuGcGM3 determines 
severity of disease [153]. Thus, while OSU can bind to multiple different gangliosides, GM3 is most 
likely the relevant attachment receptor in the porcine intestine. 
More recently, binding of VP8* from the neuraminidase-sensitive porcine CRW-8 strain to GD1a 
was analyzed by STD-NMR spectroscopy [76]. This analysis indicated that the binding epitope for 
CRW-8  encompasses  both  the  terminal  and  internal  2,3-linked  sialic  acid  moieties  of  GD1a  
(Figure  5).  The  specificity  of  this  interaction  was  confirmed  by  infectivity  studies,  in  which  pre-
incubation with the homologous VP8* or Neu5Ac2Me but not a heterologous VP8* (from human Wa 
strain) decreased infection.  Viruses 2010, 2                                       
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Figure  5.  Schematic  overview  of  O-,  A-  and  B-series  gangliosides  discussed  in  text. 
Abbreviations:  Glu:  glucose,  Gal:  galactose,  GluNAc:  N-acetylglucosamine,  GalNAc: 
N-acetylgalactosamine, Cer: ceramide, R: residue 
  
 
2.3.1.2. Simian rotavirus (SA11 strain) 
Binding of SA11 to neuraminidase-sensitive sialic acid moieties was recognized many years ago 
and shown to be responsible for the ability of this strain to hemagglutinate human or sheep erythrocytes 
[141].  Several  subsequent  studies  have  since  then  investigated  the  glycolipid  ligands  for  the 
neuraminidase-sensitive strain SA11 with at times conflicting results. Preferential binding of SA11 to 
GA1 but not GM1, GD1a, or GT1b is observed by TLC, and GA1 coated polystyrene beads or anti-
GA1 antibodies partially inhibit SA11 replication in MA104 cells [154]. In another study, SA11 bound 
to bovine brain material (primarily containing GM1, GD1a, GD1b, GT1b, Gd1b, some GD3, GT1a and 
traces of GQ1b) or isolated GM1 by Enzyme-linked immunosorbent assay (ELISA), and gangliosides 
from bovine brain material or isolated GM1 partially inhibited SA11 infection of monkey kidney LLC-Viruses 2010, 2                                       
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MK2  cells  in  a  dose-dependent  manner  [155].  Furthermore,  the  reduced  susceptibility  of 
neuraminidase-treated LLC-MK2 cells is partially restored by addition of bovine brain material or 
purified GM1. GA1 was not tested in this study. In a third study, glycolipids from the small intestine of 
Swiss  Webster  mice  were  separated  by  TLC  and  tested  for  binding  to  iodinated  SA11  [156]. 
Characterization and comparison to synthetic glycolipids suggested binding to neutral GA1 and GA2, 
but not the sialic acid-containing derivatives GM1, GM2 (Figure 5). SA11 binding to GA1 was higher 
compared to GA2 in microtiter wells, and soluble GA1 was far superior to GA2 in inhibiting SA11 
binding to adsorbed GA1 or GA2 in this assay. Due to the virus purification protocol, the contribution 
of double-layered or triple-layered particles to these binding profiles remains unclear. In addition, the 
relevance of the neuraminidase-dependent interaction of SA11 with these molecules during infection is 
unclear,  as  GA1,  GA2  and GM1 have no neuraminidase-insensitive sialic acid  groups (Figure 5), 
respectively. Therefore, the ability of CsCl-purified triple- but not double-layered particles from the 
neuraminidase-sensitive simian rotavirus SA11 to bind to 32 different gangliosides was tested by TLC 
[77].  Triple-layered  SA11  particles  bind  to  the  terminal  sialic  acid  residues  of  NeuGcGM3, 
sialylneolactotetraosylceramide  (NeuAc3Gal4GlcNAc3Gal4Glc1Cer),  GM2  and  GD1a.  This 
suggests the minimal ganglioside binding epitope of SA11 is sialyl-galactose (NeuGc/NeuAc3-Gal) 
with a preference for N-glycolyl groups.   
2.3.1.3. Bovine rotavirus (NCVD, UK strain) 
Bovine  rotaviruses  are  important  veterinary  pathogens  causing  calf  scour  and  include  both 
neuraminidase-sensitive and -insensitive strains. Bovine rotavirus NCVD is a neuraminidase-sensitive 
strain that hemagglutinates erythrocytes and binds and infects MA104 cells [157]. In addition to SA11, 
Delorme  et  al.  [77]  also  tested  the  ability  of  CsCl-purified  triple-layered  particles  from  the 
neuraminidase-sensitive NCVD and the neuraminidase-insensitive UK by TLC. Like SA11, NCVD 
and  UK  bind  to  sialylneolactotetraosylceramide  (NeuAc3Gal4GlcNAc3Gal4Glc1Cer),  GM2 
and GD1a but NCVD binds to the terminal sialic acid residues of NeuGcGM3 while UK binds to the 
internal sialic acid residues of NeuAcGM3 and GM1. Therefore, the proposed minimal ganglioside 
binding epitope for NCVD (like SA11) is sialyl-galactose (NeuGc/NeuAc3-Gal). The same minimal 
structure is found in all gangliosides recognized by UK (with a preference for NeuAc), but additional 
factors must play a role to explain the different ganglioside binding profile of UK. Interestingly, the 
main ganglioside found in the intestinal epithelium of two-day old calves is GM3 (NeuGc and NeuAc), 
with lower amounts of NeuGcGM2, NeuGcGM1 and NeuGcGD1a, while NeuGcGD2 (not bound by 
NCVD) is the major ganglioside in the adult bovine intestine [77]. Thus, NeuAcGM3 and NeuGcGM3 
may represent the main attachment receptors in vivo for UK and NCVD, respectively. 
2.3.1.4. Rhesus rotavirus (RRV strain) 
RRV  binding  to  Caco-2  and  MA104  cells  in  culture  and  intestines  of  mice  is  sensitive  to 
neuraminidase treatment [137,158,159]. NMR spectroscopy demonstrates that the protease-resistant 
core of RRV VP8 binds -anomeric N-acetylneuraminic acid with a Kd of 1.2 mM independent of the 
2-6 or 2-3 linkage in sialyllactose  [78]. However, a strong preference for N-acetyl neuraminic acid 
(Kd of 1.2 mM) was observed over N-glycolyl neuraminic acid (Kd of 11 mM). A binding constant in a Viruses 2010, 2                                       
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similar range (Kd of 0.30 mM) was determined by isothermal titration calorimetry of RRV VP8* to 
Neu5Ac2Me [160]. 
X-ray crystallography of the RRV VP8* core bound to 2-O-methyl--D-N-acetyl neuraminic acid 
and NMR spectroscopy of the unliganded core demonstrated that the sialic acid binding site is located 
in an open-ended, shallow groove formed at one edge by two  -sheets [161]. No major structural 
changes are observed upon binding but local changes suggest a binding-induced fit of sialic acid in its 
recognition site. A similar structure (root mean square deviation less than 0.22 Å) was obtained when 
RRV and VP8* are crystallized at room temperature [160]. The VP8* core is a single globular domain 
of an 11-stranded anti-parallel -sandwich that shares the same fold (but not the carbohydrate binding 
site)  as  the  galectins  (S-type  lectins),  which  bind  -galactoside-containing  oligosaccharides  [161]. 
Similar to other viral sialic acid binding proteins (e.g., influenza hemagglutinin, polyomavirus VP1), 
interaction of hydrogen bonds from amino acids, water-mediated contacts, and van der Waals contacts 
with aromatic rings contribute to the interaction between protein and ligand. The key residues of VP8* 
that mediate contact directly with sialic acid’s glycerol chain and carboxylate group are R101 and 
S190, respectively. Mutation of R101 or S190 to alanine results in reduced sialic acid binding [160]. 
Wildtype,  R101A,  and  S190A  VP8*  are  able  to  compete  with  RRV  infection  of  MA104  cells. 
However, mutant VP8* competition was less effective compared to wt VP8*. The wt and R101A 
mutant VP8* also inhibited RRV infection of neuraminidase-treated cells, leading to the suggestion 
that the sialic acid binding cleft also interacts with the aglycon portion of cell surface glycans.  
2.3.2. Neuraminidase-insensitive human rotaviruses (KUN, MO, DS-1, Wa strains) 
Human rotavirus infection is typically not affected by neuraminidase treatment, nor do these strains 
hemagglutinate  fresh  erythrocytes  [79,157].  The  human  rotaviruses  KUN  and  MO  strains  infect 
MA104 cells in a neuraminidase-insensitive manner [79]. To identify the GSL required for infection, 
TLC  and  immunostaining  were  used  to  identify the GSLs  expressed on MA104 cells,  mainly the 
gangliosides GM1 and GM3 and the neutral GSL lactosylceramide (Figure 5). Of those, the sialic acid 
moiety of GM1 is insensitive to neuraminidase treatment. Addition of exogenous GM1 but not GA1 
(i.e., asialo-GM1) to MA104 cells inhibited infection with KUN and MO but not the neuraminidase-
sensitive feline rotavirus strain FRV64. In addition, cholera toxin B subunit, which binds to GM1, is 
able to block infection with KUN and MO, but not FRV64. Hence, GM1 is a receptor for human KUN, 
MO strains in MA104 cells. 
Metrizamide  gradient  purified  (i.e.,  preparation  containing  triple-  and  double-layered  particles) 
human  Wa  and  DS-1  rotavirus strains  recognize GA1 but  not  GM1, GD1a, GT1b in  TLC  [154]. 
However, by STD-NMR spectroscopy VP8* of the strain Wa clearly shows binding to the internal 
2,3-linked sialic acid moiety of GM1 and the branchpoint sugars (Gal, GalNAc) [76]. The specificity 
of this interaction was confirmed by infectivity studies, in which pre-incubation with the homologous 
VP8* but not heterologous VP8* (neuraminidase-sensitive porcine CRW-8 strain) or competition with 
cholera  toxin  B  subunit  (which  specifically  binds  to  GM1)  decreased  infection.  Interestingly,  Wa 
binding and infection was increased upon neuraminidase treatment, suggesting that removal of terminal 
sialic acids increases Wa receptor binding by exposing additional receptors, e.g., converting GD1a into 
GM1. Viruses 2010, 2                                       
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Analogous  to  RRV  VP8*,  the  crystal  structure  of  the  VP8*  core  from  the  neuraminidase-
independent  human  rotavirus DS-1 was  also  solved and shows the same galectin-like fold with  a 
slightly wider groove than the sialic acid binding site in the RRV VP8* core [162]. In DS-1 the R101 is 
replaced by phenylalanine, which interacts with an adjacent -sheet but does not contribute to any 
surface interactions. However, the adjacent extended binding region is highly conserved between the 
VP8* cores of RRV and DS-1 and capable of interacting with other more internal SA linkages [163]. 
2.4. Polyomaviridae 
The Polyomaviridae family is a group of small double-stranded DNA viruses and derives its name 
from the ability of the viruses to form multiple tumors in mammals. All the members have a similar 
genome organization and capsid structure [164]. The ~5kb circular genome forms a minichromosome 
with cellular histones and is encapsidated in an icosahedral virion  [165-168]. The capsid is composed 
of 360 copies of the major capsid protein VP1, arranged in 72 pentamers linked by disulfide bonds and 
stabilized by calcium  bridges  [165,168].  Each pentamer interacts  with  a single copy of the minor 
capsid protein VP2 or VP3, which connects the viral DNA genome with the outer capsid shell [81]. 
VP1 is able to self-assemble into VLPs in vitro [169], and it contains the binding sites for the cellular 
receptors [170-172]. These viruses display a narrow host range and the interactions between the capsid 
and  the  receptors  are  an  important  determinant  of  viral  tropism  as  reconstitution  of  certain  non-
permissive cells with the appropriate ganglioside can confer infectivity [83,173-175]. A number of 
receptors including gangliosides and glycoproteins are used by the polyomaviruses [176] (Table 1). 
Following the initial attachment to the cell surface, most polyomaviruses are internalized via either 
caveolin-  or  clathrin-  mediated  endocytosis  [177-182].  Although  they  traffic  through  different 
endocytic compartments, all the polyomaviruses studied so far seem to converge in the ER, where viral 
capsid disassembly and membrane penetration are believed to occur [180,183-186]. There is also some 
recent evidence suggesting that the ganglioside receptors may govern the intracellular destination of 
these viruses [187]. In this section of the review, we will focus on the interactions between these 
viruses and various gangliosides.  
2.4.1. Murine Polyomavirus (MPyV) 
MPyV was the first polyomavirus discovered (recovered from murine leukemia-causing extracts) 
[188]  and  was  originally  found  to  utilize  sialic  acid-containing  receptors  in  the  1980s  [189-191]. 
Treatment of human erythrocytes or murine 3T6 cells with neuraminidase that removes terminal sialic 
acids  abolishes  MPyV  hemagglutination  and  prevents  viral  infection,  respectively  [190,191]. 
Subsequent  restoration  of  the  cells  with  α2,3-linked  sialic  acids  is  able  to  reconstitute  these 
characteristics, suggesting a specific recognition of these sugar moieties [190,191]. Certain strains of 
MPyV  are  also  able  to  bind  to  a  second  α2,6-linked,  branching  sialic  acid  [189].  The  molecular 
determinant for binding to α2,3- or α2,6-linked sialic acid is a single-amino-acid difference in VP1 
(residue 91 Glu versus Gly) that accounts not only for the receptor binding specificity difference but 
also  changes  in  plaque  size,  hemagglutination  properties,  and  tumor  induction  ability  [192,193]. 
Crystal structures have shown that a shallow groove composed of several loops of VP1 on the virion 
surface  accommodates  these  sialic  acids  [81,171].  These  loops  may  be  important  in  determining Viruses 2010, 2                                       
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receptor specificity, as they display sequence variation among polyomaviruses [170,172]. The side 
chain of the Glu91 prevents the interactions with the carboxylate of the branched α2,6-linked sialic 
acid, thus explaining the differences in the second sialic acid binding  [81]. Furthermore, biochemical 
studies demonstrated that MPyV has a low affinity for its receptors (with dissociation constants in the 
mM range) and these weak interactions are thought to result in more efficient release of the virion from 
the receptors, and therefore more rapid spread and increased pathogenicity [168,170]. This concept was 
further supported by the fact that the highly virulent LID strain of MPyV also has reduced virus-sialic 
acid interactions [174].   
It was not until 2003 though when the true identity of the MPyV receptor was discovered [80]. 
Using a sucrose floatation assay, Tsai et al. demonstrated that the gangliosides GD1a and GT1b allow 
the virus to float to the lighter fractions in sucrose gradients [80]. Furthermore, supplementation of 
non-permissive rat or mouse cells with GD1a can restore MPyV infectivity [80,194]. The terminal 
α2,3-linked sialic acid linked to the Gal sugar moiety of GD1a and GT1b are most likely in contact 
with VP1, based on modeling of these two gangliosides onto the VP1-oligosaccharide crystal structure 
[80] (Figure 5). The binding pocket for the α2,6-linked sialic acid in the crystal structure does not seem 
to interact with these gangliosides; instead, it may be involved in binding to glycoproteins [80,81]. 
Consistent with this, the glycoprotein α4β1 integrin has been suggested as a co-receptor for MPyV at a 
post-attachment level  [82,83]. Addition of GD1a to rat C6 glioma cells or murine NIH 3T3 cells 
increases  the  co-localization  between  the  ER  and  MPyV,  and  facilitates  a  productive  infection 
[80,187]. Coating an artificial particle with GD1a is sufficient to deliver it to the ER, suggesting that 
ganglioside binding may serve as a general ER targeting signal [187]. Whether this also applies to 
other polyomaviruses binding to their respective gangliosides, remains to be determined.    
2.4.2. Simian Virus 40 (SV40) 
SV40  was  identified  as  a  contaminant  of  cell  cultures  that  were  used  for  poliovirus  vaccine 
production  [195]. It turns out, however, to have been an invaluable tool to study many fundamental 
questions in molecular biology [164]. Whether SV40 is a human pathogen remains controversial [196]. 
Early studies suggested that SV40 did not recognize sialic acids [197], but this was later disproven. 
The ganglioside GM1 was identified to be the cellular receptor for SV40 at the same time that the 
MPyV receptors were identified [80]. Similar to the MPyV-receptor interactions, the binding of GM1 
to  SV40  is  relatively  weak  [172].  A  high  resolution  crystal  structure  obtained  from  SV40  VP1 
pentamers,  with  or  without  a  GM1-derived  oligosaccharide,  reveals  that  there  are  no  major 
conformational changes in VP1 upon GM1 binding [172]. VP1 binds to both the internal α2,3-sialic 
acid  and Gal-β1,3-GalNAc of GM1 (Figure 5) in  a shallow groove, which may explain the strict 
specificity of SV40 for GM1 [172]. Although both SV40 and MPyV bind to α2,3-linked sialic acids, 
the  binding  occurs  in  different  orientations  and  conformations  for  these  two  viruses  [172].  A 
carbohydrate  microarray  screen  identified  that  the  simian-derived  N-glycolyl  GM1  ganglioside 
[GM1(Gc)] is a better receptor for SV40 than GM1 [198]. The differences may lie in the higher affinity 
of a deeper pocket formed by two externalized loops of VP1 for the additional hydrophilic hydroxyl 
group present in GM1(Gc) [172, 198]. During attachment to cells SV40 also interacts with its co-Viruses 2010, 2                                       
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receptor,  the  class  I  major  histocompatibility  proteins  to  enter  cells  in  a  caveolin-dependent  
or -independent manner [84,85,181,199,200].  
The  interaction  between  SV40  and  GM1  is  a  dynamic  process.  Kukura  et  al.  developed  a 
methodology that combines interferometric scattering detection with single-molecule microscopy to 
track single quantum dot-labeled SV40 VLPs on supported lipid bilayers [201]. They observed both 
sliding and tumbling motions of VLPs, suggesting a rapid exchange between the VP1 pentamers and 
the GM1 receptors. They also observed back and forth rocking motions between distinct nanodomains 
when GM1 was present at a high concentration, which presumably results from the existence of small 
GM1 aggregates [201]. After the initial interaction of SV40 with GM1, invagination of the membrane 
is required for successful entry. A recent study showed that the binding of SV40 particles or VP1 
pentamers  to  GM1  alone  is  sufficient  to  induce  membrane  curvatures  that  can  proceed  to  form 
membrane tubules [202]. Using the murine cell line GM95, deficient in glucose-based glycolipids and 
supplemented with various GM1 species, the authors demonstrated that the length of the acyl chain of 
the lipid moiety and not the ceramide base of GM1 is crucial for the endocytosis and the establishment 
of a productive infection of SV40  [202]. This formation of the membrane curvatures is caveolin-
independent.  A  similar  observation  has  also  been  made  with  MPyV  [202].  These  data  led  to  the 
proposal  that  the  receptor  binding  sites  present  in  the  pentamers  can  induce  lipid  clustering  and 
invagination and eventually lead to caveolin-independent endocytosis [202].     
2.4.3. BK virus (BKV) and JC virus (JCV) 
BKV and JCV are two well-established human polyomaviruses. They were identified in the same 
year and were both named after the initials of the patients from whom they were isolated [203,204]. 
BKV is the causative agent of polyomavirus-associated nephropathy in renal transplant patients and of 
hemorrhagic cystitis in bone marrow transplant recipients, whereas JCV is known to be associated with 
progressive  multifocal  leukoencephalopathy,  a  demyelinating  central  nervous  system  disease  in 
immunosuppressed individuals [205]. Using a sucrose floatation assay in vitro, BKV was found to bind 
to gangliosides GD1b and GT1b [86]. Compared to GM1, both GD1b and GT1b carry an additional 
α2,8-linked sialic acid motif that may be uniquely recognized by BKV [86] (Figure 5). Addition of 
these gangliosides to non-permissive cells confers susceptibility to BKV infection in vivo [86]. There is 
also some conflicting evidence regarding the usage of sialylated glycoproteins as cellular receptors by 
BKV. Restoration of sialylation on N-linked glycoproteins in sialic acid-stripped cells restores BKV 
infectivity  [87].  Treatment  with  proteinase  K,  however,  does  not  affect  BKV  interaction  with 
membranes [86]. The ganglioside usage of JCV in cells is not well characterized but there is limited 
evidence pointing to the involvement of GT1b in JCV infection in susceptible human neuroblastoma 
IMR-32 cells [88]. By TLC, JCV VLPs bind to lactosylceramide, GM3, GD2, GD3, GD1b, GT1b, 
GQ1b, and weakly to GD1a but not to GM1a, GM2, or galactocerebroside [88,206] (Figure 5). An N-
linked glycoprotein with α2,6-linked sialic acids and the serotonin receptor 5HT2aR serve as receptors 
for JCV in glial cells [89-91].  
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2.4.4. Merkel Cell Polyomavirus (MCPyV) 
MCPyV is a newly discovered polyomavirus from Merkel cell carcinomas (MCC), an aggressive 
form of skin cancer [207]. The viral DNA was found in a high frequency of MCC tumors, suggesting a 
causal relationship between MCPyV and MCC [205]. Although no infectious virion has been isolated 
for  MCPyV,  the  ganglioside  GT1b  was  suggested  to  be  a  cellular  receptor  based  on  experiments 
performed with MCPyV VP1 capsomeres [92]. The fact that only GT1b, but not GD1a or GD1b, 
confers binding to MCPyV VP1 indicates that both the 2,3-linked terminal and 2,8-linked internal 
sialic acids of GT1b are required for the interaction [92] (Figure 5).    
2.5. Parvoviridae 
The Parvoviridae family contains small icosahedral viruses with a single-stranded DNA genome of 
approximately 5 kb [208]. The genome is flanked by terminal repeats required for DNA replication, 
encodes one or two nonstructural proteins (NS1, NS2) required during viral replication, and 2-3 capsid 
proteins  (VP1,  VP2  and  sometimes  VP3),  which  form  the  viral  capsid.  Replication  occurs  in  the 
nucleus. The Parvoviridae family is divided into two subfamilies, the Parvovirinae and Densovirinae, 
which infect mammalian and invertebrate hosts, respectively. The former is further subdivided into five 
genera, of which members of the genera Dependovirus (bovine adeno-associated virus, BAAV) and 
Erythrovirus (human parvovirus B19, simian parvovirus) will be discussed here because they interact 
with gangliosides and globosides, respectively.   
2.5.1. Erythroviruses 
Erythroviruses belong to the autonomous parvoviruses [208]. These viruses are species-specific and 
have a narrow host range for hematopoietic progenitor cells. They are replication competent but do not 
induce cell division and thus only infect cells going through S phase that have the required host cell 
component to initiate DNA synthesis. Their genome encodes two structural proteins, VP1 and VP2, 
and the nonstructural protein NS1, with the inherent ability of VP2 to self-assemble into VLPs.  
2.5.1.1. Human parvovirus B19 
Human Parvovirus B19 was identified in 1975 in serum from infected patients (for review see 
[209]). It is the causative agent of erythema infectiosum (Fifth disease) as well as anemia, arthropathy 
(joint disease), and fetal loss. Transmission occurs through the respiratory tract, by blood transfusion or 
in utero. B19 binds to erythroid precursors and their destruction accounts for the anemia associated 
with  B19  infections  in  patients  with  high  red  cell  turnover.  One  of  the  receptors  utilized  on  the 
erythrocyte surface by B19 is globoside.  However, while globoside is necessary for B19 binding, it is 
not sufficient for virus entry into cells [95]. The co-receptor required for viral entry of erythrocyte 
precursors  is  51  integrin  [95].  Thus,  in  case  of  mature  red  blood  cells,  which  highly  express 
globoside  but  not  51  integrin,  B19  can  bind  to  but  not  enter  these  cells  [95].  In  addition  to 
erythrocytes, B19 can also infect other immune cells like T cells, B cells, macrophages and follicular 
dendritic cells [210]. On non-erythrocyte cells, the autoantigen Ku80 functions as a co-receptor to 
mediate binding and entry of B19 [96]. While globoside was the first receptor for B19 to be identified, Viruses 2010, 2                                       
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it is not the only one utilized.  Further studies are required to fully delineate the repertoire of cell 
surface molecules and sequence of events required during viral entry.   
For the purpose of this review, we will focus only on globoside, also called blood group P antigen, 
because it is a neutral GSL in the globo-series [7]. The blood group P antigen system contains three 
major antigens P1, P (both common), and P
k (rare). P is the globoside Gb4 (globotetraosylceramide), P
k 
is  Gb3  (globotriaosylceramide),  and  P1  is  an  4Gal-structure  on  the  paragloboside  structure  [7]  
(Figure 6). Globoside was identified as the cellular receptor for B19 through a series of biochemical 
and competition experiments. B19 VLP could hemagglutinate red blood cells from individuals with the 
P1 phenotype (carry P and P1 antigens) and P2 phenotype (P antigen) but not p phenotype (lack all three 
antigens) [93], and only individuals with the rare p phenotype (Gal1,4Glc-Cer) are not infected with 
B19 [211]. Biochemical analysis of B19 VLP binding to purified GSLs by TLC demonstrated binding 
to globoside Gb4 and Forssmann antigen but not P
k [93] (Figure 6). Furthermore, B19 infection of late 
erythroid-colony forming units (CFU-E) was blocked by either competition with globoside or an anti-
globoside monoclonal antibody [93]. Subsequent analysis of additional neutral GSL from multiple 
tissues identified additional weak binding of B19 VLPs binding to two globoseries GSLs (SSEA-3, 
SSEA-4)  and  nLc4  (neolactotetraglycosylceramide)  [94]  (Figure  6),  which  are  part  of  the  same 
biosynthetic pathway as P antigen [7]. This indicates the minimal carbohydrate binding epitope may be 
the GluNAc/GalNAc1,3Gal sequence shared between all [94] (Figure 6). Cryo-electron microscopy 
studies  of  B19  VLPs  with  globoside  followed  by  computer  modeling  indicate  that  the  globoside 
receptor likely binds to the hydrophobic depressions at the icosahedral  three-fold axis of the viral 
capsid as a trimer [212]. 
Figure  6.  Comparison  of  discussed  carbohydrate  structures  used  during  attachment  of 
parvovirus  B19.  Schematic  representation  of  nLC  and  Gb  attachment  receptors  in 
comparison to the non-binding globoside Gb3. Abbreviations: Glu: glucose, Gal: galactose, 
GluNAc: N-acetylglucosamine, GalNAc: N-acetylgalactosamine, Cer: ceramide, R: residue 
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2.5.1.2. Simian parvovirus (SPV) 
SPV is  closely related to  B19 (for review see  [213]). It was identified in 1992 in cynomolgus 
macaques  (Macaca  fascicularis)  co-infected  with  immunosuppressive  type  D  simian  retrovirus. 
Experimental  infection  of  cynomolgus  macaques  shows  similar  symptoms  to  B19  infections  in 
humans, i.e. transient anemia (decrease in red blood cells) and reticulocytopenia (decrease in immature 
red blood cells), decreased erythroid and myeloid lineages in the bone marrow, and hydrops fetalis 
(accumulation of fluid in fetal compartments) and fetal death in pregnant animals. Like B19, SPV also 
uses globoside on the erythrocyte precursors and is able to infect human bone marrow mononuclear 
cells  [97].  Specifically,  SPV  VP2  VLPs  were  shown  to  hemagglutinate  human  erythrocytes. 
Hemagglutination was blocked by globoside and Forssmann antigen, which differ by an additional 
GalNAc group in the latter (Figure 6), but not other GSL (lactosylceramide, ceramide trihexoside, 
asialoganglioside GM2). Whether SVP can bind to additional neutral GSL like B19 remains to be 
determined.  
2.5.2. Dependoviruses 
Adeno-associated viruses (AAVs) are nonpathogenic viruses that depend on a helper virus (mostly 
adenovirus or herpesvirus) for replication [208]. AAVs latently infect their hosts by integrating into the 
host DNA while lytic infection and production of infectious virus occurs only in the presence of a 
helper virus. AAVs are typically detected as contaminants of viral stocks from primate, human, avian, 
bovine, ovine, or equine origin. Recombinant AAVs are promising vectors for gene therapy because of 
their nonpathogenic nature, broad tropism, ability to transduce dividing and non-dividing cells and 
ability for long-term expression in vivo [214]. The diverse tropisms of AAVs are due to differences in 
receptor usage. However, the only AAV shown to date to require GSL for infection is bovine AAV 
(BAAV) [98]. 
BAAV  like  the  related  AAV4  and  AAV5  requires  sialic  acid  during  infection  [98].  BAAV 
transduction  of  cells  was  reduced  by  treatment  with  several  exoneuraminidases,  including  the 
neuraminidase  from  S.  pneumoniae,  which is  specific for  2-3 linked sialic acid,  and blocked by 
competition with wheat germ agglutinin, a sialic acid-binding lectin [98]. Interestingly, binding of 
BAAV in contrast to AAV5 was not blocked by removal of terminal sialic acids. BAAV binding and 
transduction were protease resistant, and transduction and DNA uptake but not binding were blocked 
by  glycosylceramide  synthase  inhibitors.  Incorporation  of  gangliosides  but  not  neutral  GSLs  into  
GSL-depleted  COS  or  ganglioside-deficient  C6  cells  was  able  to  restore  transduction.  These  data 
demonstrate  that  BAAV  requires  gangliosides  for  transduction,  probably  at  the  level  of  virus 
internalization [98]. However, the specific ganglioside(s) mediating this step in the viral life cycle 
remains to be identified. 
3. Conclusions 
GSLs are a group of molecules with a large carbohydrate head group and a lipid tail, which inserts 
into the cell membrane. Due to many different possible modifications in both the sugar and the lipid 
portion, these molecules exhibit great diversity that is not only cell type- and tissue-dependent, but also Viruses 2010, 2                                       
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changes  during  differentiation,  activation  of  cells,  as  well  as  during  ontogenic  development  and 
hematopoiesis.  Many  viruses  take  advantage  of  these  specific  patterns  on  the  cell  surface  for 
recognition  of  target  cells.  For  example,  expression  of  specific  GSLs  during  individual  stages  of 
development is a likely reason for the observed age-dependent disease manifestation of rotaviruses in 
young animals or older animals for RHDV. Conversely, the lack of expression of a given GSL can 
result in natural resistance to a given viral disease, e.g., inability of B19 to infect individuals of the p 
phenotype that lack globoside. Furthermore, a given glycan repertoire on the cell surface can have a 
profound impact on viral evolution and epidemiology. For example, individual norovirus strains may 
only infect a subset of the population, but through slight changes in the binding site different strains 
cover a wide range of binding profiles so that any individual in the population is at risk of being 
infected. Receptor switching and changing antigenicity then allows the virus to successfully escape the 
host  immune  system  and  expand  into  naive  populations.  In  addition,  the  typically  weak  binding 
affinities  of  GSL  and  their  ligands  makes  them  ideal  candidates  for  attachment  receptors  that 
concentrate viruses (and other microbes) near the cell surface to enable interaction with additional 
receptor molecules that facilitate internalization. Virus interaction with a GSL typically occurs via the 
carbohydrate portion, while the lipid portion, in case GSLs serve as viral entry receptors, controls the 
intracellular fate of these viruses.  Thus, for most virus families discussed in this review (calici-, rota-, 
and parvoviruses), GSLs merely serve as attachment receptors that facilitate binding to the cell surface 
but not endocytosis. Endocytosis of these viruses depends on the interactions between the virus and 
other receptor molecules. However, for viruses that utilize GSLs as an entry receptor, such as the 
polyomaviruses discussed herein, the intracellular trafficking of the virus is governed by specific virus-
GSL interactions.  In the case of MPyV, for example, the entry receptor GD1a targets the virus to the 
ER [187]. The fact that all polyomavirus studied so far travel to the ER despite interacting with various 
gangliosides displaying differing sugar moieties suggests that the lipid portion of the GSL is important 
for controlling the intracellular transport of the viruses.  In fact, SV40 endocytosis is governed by the 
acyl chain length of GSLs [202]. The driving force for endocytosis may be a virus-induced clustering 
of GSLs leading to formation of membrane tubules/invaginations as each individual capsid protein 
within a repeating subunit (i.e., SV40 VP1 pentamer) binds to GM1 [202]. Similarly, interaction of 
Shiga toxin B subunit, which is active only in its pentameric form, with its receptor Gb3 induces 
narrow tubular membrane invaginations [215]. While membrane invaginations can clearly form within 
model  membranes  in  both  cases  [202,215],  further  work  is  needed  to  determine  whether  GSL 
clustering alone or clustering induced recruitment of proteins is required for targeted trafficking of the 
respective ligand.   
In summary, GSL-virus interactions are a common feature of viruses from multiple different virus 
families  and  represent  an  attractive  anti-viral  target.    However,  the  varying  intricacies  of  such 
interactions need to be taken into account when designing GSL-mimics that can effectively block virus 
binding to host cells.  
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